We protect your health through science
Investigation
Antibiotic Resistance
Research Lines
Content with Investigacion .
Hepatitis
- Diseño de métodos diagnósticos para el estudio de los virus de las hepatitis (VH) A, B, C, D, E: Diseñamos sistemas de PCR para su detección y caracterización.
- Evaluación de métodos diagnósticos de los VH. Colaboramos con empresas para estudios de sensibilidad y especificidad de equipos diagnósticos.
- Estudios de Seroprevalencia de los virus de las hepatitis.
- Epidemiología genómica de genomas completos de VHA, VHB, VHC, VHD y VHE en colaboración con el ECDC. Estudios de trazabilidad del VHE.
- Caracterización molecular de virus de las hepatitis mediante secuenciación masiva: a) VHB: mutantes de escape HBsAg (prevalencia y efectos en la detección del HBsAg). Estudio de mutaciones en epítopos de estimulación inmune y mutaciones asociadas a evolución clínica desfavorable.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
c) Estudios filogenéticos del VHD.
d) Análisis genómico del VHE.
e) Investigación etiológica de hepatitis no filiadas mediante estudios de metagenómica.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
Research projects
Content with Investigacion .
1. Proyecto CIBEREPS 2022. Microbiological and genomic investigation of hepatitis in children by metagenomic approach in case and control subjects (IP: Ana Avellón).
2023-2024. En colaboración con el Hospital San Joan de Deu de Barcelona.
2. MPY 501-19: Tracking hepatitis E virus infection by means of epidemiological research and whole genome sequencing. Project TrazHE. (IP: Ana Avellón). 2020-2024.
3. Proyecto CIBEREPS 2021 Metagenomic sequencing to identify viral aetiologies in undiagnosed paediatric cases of meningitis and encephalitis (IP: D. Tarragó). 2021-2022.
4. MPY 383/19 (PEJ2018-004446-A). Ayudas para la promoción de empleo joven e implantación de la garantía juvenil en I+D+I. análisis de la complejidad de secuencias de los virus de la hepatitis A, B, C; D y E (VHA, VHB, VHC, VHD y VHE) mediante técnicas de secuenciación masiva. (IP: Ana Avellón). 2020-2021.
5. MPY 1285/16 Movilidad "Salvador de Madariaga" programa estatal de promoción de talento y su empleabilidad. (IP: Ana Avellón). 2016.
Publications
Potential implication of azole persistence in the treatment failure of two haematological patients infected with Aspergillus fumigatus
Peláez-García de la Rasilla T, Mato-López A, Pablos-Puertas CE, González-Huerta AJ, Gómez-López A, Mellado E, Amich J. Journal of Fungi, 2023 Jul 30;9(8):805.
PUBMED DOIAspergillus fumigatus can exhibit persistence to the fungicidal drug voriconazole
Valero C., Á Mato-López, I J. Donaldson, A. Roldán, H. Chown, N. Van-Rhijn, S. Gago, T. Furukawa, A. Mogorovsky, R. Ben Ami, P. Bowyer, N. Osherov, T. Fontaine, G.H. Goldman, E. Mellado, M. Bromley and J. Amich. Microbiology Spectrum.2023 13;11(2):e0477022
PUBMED DOICOVID-19 Associated Pulmonary Aspergillosis (CAPA): Hospital or Home Environment as a source of life-threatening Aspergillus fumigatus infection?
Peláez-García de la Rasilla T, González-Jiménez I, García-Fernández Arroyo A, Roldán A, Carretero-Ares JL, Clemente-García M,, Martínez-Suarez M, Vázquez Valdés F, Melón-Garcia S, Mellado E, Sánchez-Nuñez ML on behalf HUCAPA group. Journal of Fungi, 2022 Mar 19;8(3):316.
PUBMED DOIThe sulfur-related metabolic status of Aspergillus fumigatus during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target
Alharthi R, Sueiro-Olivares M, Storer I, Bin Shuraym H, Scott J, Al-Shidhani R, Fortune-Grant R, Bignell E, Tabernero L, Bromley M and Amich J. 2025. Virulence, 16(1):2449075
PUBMED DOIGuasp, P., E. Lorente, A. Martín-Esteban, E. Barnea, P. Romania, D. Fruci, J. J. W. Kuiper, A. Admon, and J. A. López de Castro. 2019. Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-Associated HLA-B*51 Peptidome. Mol.Cell Proteomics.
Guasp, P., E. Lorente, A. Martín-Esteban, E. Barnea, P. Romania, D. Fruci, J. J. W. Kuiper, A. Admon, and J. A. López de Castro. 2019. Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-Associated HLA-B*51 Peptidome. Mol.Cell Proteomics.
PUBMED DOIProteomics analysis reveals that structural proteins of the virion core and involved in gene expression are the main source for HLA class II ligands in vaccinia virus-infected cells.
Lorente, E., Martin-Galiano, A. J., Barnea, E., Barriga, A., Palomo, C., Garcia-Arriaza, J., Mir, C., Lauzurica, P., Esteban, M., Admon, A., and Lopez, D. (2019) Proteomics analysis reveals that structural proteins of the virion core and involved in gene expression are the main source for HLA class II ligands in vaccinia virus-infected cells. J.Proteome.Res. 18(9):3512-3520
PUBMED DOIComputational characterization of the peptidome in transporter associated with antigen processing (TAP)-deficient cells.
Martin-Galiano, A. J. and Lopez, D. (2019) Computational characterization of the peptidome in transporter associated with antigen processing (TAP)-deficient cells. PLoS.ONE. 14, e0210583.
PUBMED DOILorente, E., A. Barriga, E. Barnea, C. Palomo, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2019. Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. PLoS.Negl.Trop.Dis. 13:e0007547.
Lorente, E., A. Barriga, E. Barnea, C. Palomo, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2019. Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. PLoS.Negl.Trop.Dis. 13:e0007547.
PUBMED DOILópez, D., A. Barriga, E. Lorente, and C. Mir. 2019. Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design. J.Clin.Med. 8.
López, D., A. Barriga, E. Lorente, and C. Mir. 2019. Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design. J.Clin.Med. 8.
PUBMED DOIBrait, V. H., F. Miro-Mur, I. Perez-de-Puig, L. Notario, B. Hurtado, J. Pedragosa, M. Gallizioli, F. Jimenez-Altayo, M. Arbaizar-Rovirosa, A. Otxoa-de-Amezaga, J. Monteagudo, M. Ferrer-Ferrer, l. R. de, X, E. Bonfill-Teixidor, A. Salas-Perdomo, A. Hernandez-Vidal, P. Garcia-de-Frutos, P. Lauzurica, and A. M. Planas. 2019. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Circ.Res. 124:279-291.
Brait, V. H., F. Miro-Mur, I. Perez-de-Puig, L. Notario, B. Hurtado, J. Pedragosa, M. Gallizioli, F. Jimenez-Altayo, M. Arbaizar-Rovirosa, A. Otxoa-de-Amezaga, J. Monteagudo, M. Ferrer-Ferrer, l. R. de, X, E. Bonfill-Teixidor, A. Salas-Perdomo, A. Hernandez-Vidal, P. Garcia-de-Frutos, P. Lauzurica, and A. M. Planas. 2019. CD69 Plays a Beneficial Role in Ischemic Stroke by Dampening Endothelial Activation. Circ.Res. 124:279-291.
DOILorente, E., J. Redondo-Anton, A. Martín-Esteban, P. Guasp, E. Barnea, P. Lauzurica, A. Admon, and J. A. López de Castro. 2019. Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis. Mol.Cell Proteomics. 18:2298-2309.
Lorente, E., J. Redondo-Anton, A. Martín-Esteban, P. Guasp, E. Barnea, P. Lauzurica, A. Admon, and J. A. López de Castro. 2019. Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis. Mol.Cell Proteomics. 18:2298-2309.
PUBMED DOILorente, E., C. Palomo, E. Barnea, C. Mir, V. M. Del, A. Admon, and D. López. 2019a. Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. J.Proteome.Res. 18:3512-3520.
Lorente, E., C. Palomo, E. Barnea, C. Mir, V. M. Del, A. Admon, and D. López. 2019a. Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. J.Proteome.Res. 18:3512-3520.
PUBMEDLorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
Lorente, E., M. G. Fontela, E. Barnea, A. J. Martín-Galiano, C. Mir, B. Galocha, A. Admon, P. Lauzurica, and D. López. 2020. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol.Cell Proteomics. 19:994-1004.
PUBMED DOIRedondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
Redondo-Anton, J., M. G. Fontela, L. Notario, R. Torres-Ruiz, S. Rodriguez-Perales, E. Lorente, and P. Lauzurica. 2020. Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. Front Genet. 11:552949.
PUBMED DOIFontela, M. G., L. Notario, E. Alari-Pahissa, E. Lorente, and P. Lauzurica. 2019
Fontela, M. G., L. Notario, E. Alari-Pahissa, E. Lorente, and P. Lauzurica. 2019. The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1. Genes (Basel) 10.
PUBMED DOIAdditional Information
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.